ALTSTATION.IO

Johnson & Johnson (JNJ) Stock Analysis

By Nova Skye | AltStation.io | Updated February 07, 2026

Price

$239.15

Change

+0.57%

Market Cap

$576.18B

Avg Volume

9.0M

Company Overview

Johnson & Johnson (JNJ) is a diversified healthcare company based in New Brunswick, New Jersey. They research, develop, manufacture, and sell a wide array of health products, including pharmaceuticals, medical devices, and consumer health items. Key areas of focus include immunology, oncology, neuroscience, and cardiovascular health. Their products reach consumers and healthcare professionals through various channels like hospitals, pharmacies, and clinics.

JNJ is a market leader in the healthcare sector, benefiting from a well-established brand and a vast product portfolio. Its Innovative Medicine segment continues to lead with drugs in high-demand therapeutic areas, while the MedTech segment maintains significant competitive advantages with cutting-edge surgical technologies. However, JNJ faces competitive pressure from other giants like Pfizer and Abbott Laboratories, along with challenges from emerging biotech companies. Ongoing patent expirations and regulatory hurdles could pose threats to its market position.

Currently, Johnson & Johnson is in a transformative phase, having announced a strategic pivot to spin off its consumer health division into a separate company. This move aims to sharpen its focus on pharmaceuticals and medtech, which have higher growth potential. Even with these changes, JNJ posted revenue growth of 5.4% in the last quarter, indicating resilience and continued demand for its core products, despite facing litigation challenges that could impact its bottom line.

Key Financials

Market Cap

$576.18B

Revenue

$94.19B

EBITDA

$33.06B

Gross Margin

68.1%

Profit Margin

28.5%

Revenue Growth

9.1%

Total Cash

$18.56B

Total Debt

$45.80B

Free Cash Flow

N/A

52-Week Price Performance Analysis

Price Statistics

P/E Ratio

21.68

Forward P/E

19.06

Beta

0.35

52-Week High

$240.24

52-Week Low

$141.50

EPS

$11.03

50-Day Avg

$212.58

200-Day Avg

$181.27

Price/Book

7.26

Technical Analysis

The 52-week chart for Johnson & Johnson (JNJ) shows a strong upward trend, with a remarkable increase of 60.4%, reflecting sustained bullish sentiment throughout the period. Key support is identified around the $140 level, which held up during pullbacks, while resistance is evident near $240, where the stock is currently trading at $239.15. Notable formations include a series of higher lows and higher highs, indicative of a well-defined uptrend, with a specific period of consolidation around $180 to $200 from April to August before the more recent price acceleration. Recent momentum has been particularly robust, with price actions suggesting strong buying pressure as it approaches the recent high established in February. Currently, JNJ sits near the top of its 52-week range, implying potential overextension, but also strong bullish momentum as it tests resistance levels that could see further breakout or retracement depending on subsequent trading volume and market sentiment.

Recent News and Developments

Market Update

Here’s a summary of the latest news and developments for Johnson & Johnson (JNJ) stock in the past week (February 1-7, 2026):

1. Numerous Analyst Upgrades and Price Target Increases

Johnson & Johnson’s stock has seen a wave of positive adjustments from analysts this past week. HSBC raised its price target from $240 to $265, maintaining a “buy” rating, which contributed to a 1.6% rise in JNJ shares. Morgan Stanley upgraded JNJ’s stock rating from “Equalweight” to “Overweight” and significantly increased its price target to $262.00. Other firms, including RBC Capital, TD Cowen, Argus, and Citigroup, also lifted their price targets for JNJ, reflecting a consensus “Moderate Buy” rating among analysts with an average price target of $233.05.

2. Positive Momentum from Strong Q4 2025 Earnings and 2026 Guidance

Although the official Q4 2025 earnings report was released in late January, its positive implications continued to drive sentiment this past week. Johnson & Johnson reported Q4 EPS of $2.46, in line with estimates, and revenue of $24.56 billion, a 9.1% year-over-year increase, exceeding analyst estimates. The company also set a strong FY 2026 guidance of $11.430-$11.630 EPS, contributing to optimism about its future growth.

Market Sentiment and Analyst Recommendations

Bull Case

JNJ just posted 9.1% revenue growth with Q4 EPS at $2.46 and raised full-year 2026 guidance to $11.43-$11.63, signaling real operational momentum. The pipeline is firing on multiple fronts: OMNYPULSE showed 100% procedural success in atrial fibrillation trials, and ERLEADA demonstrated a 51% reduction in death risk for prostate cancer patients in real-world data. Twenty-four analysts maintain buy ratings with an average target of $233.05, though HSBC and Morgan Stanley just bumped targets to $265 and $262 respectively. At 21.68x P/E, JNJ trades in line with historical averages for a company generating nearly $100B in annual revenue with defensive characteristics. The stock is up 60.4% over 52 weeks and sitting near all-time highs, but the combination of earnings beats, strong guidance, and genuine clinical wins suggests the momentum is justified, not speculative.

Bear Case

JNJ is trading at $239.15, near the top of its 52-week range, which leaves limited upside before hitting resistance and increased downside risk if sentiment shifts. The debt load of $45.8B against $18.56B in cash is manageable but not trivial, and it constrains financial flexibility if the company needs to fund major acquisitions or weather a revenue slowdown. At a $576B market cap, JNJ is a mature, slow-growth healthcare giant competing in crowded markets where regulatory risk is constant and patent cliffs remain a structural threat. The analyst target range spans $155 to $265, a 71% spread that reveals deep disagreement about valuation. Recent analyst upgrades could be late-cycle enthusiasm rather than early recognition of value, especially with the stock already up 60% in a year and priced for execution on pipeline hopes that haven’t yet translated to major revenue contributions.

What to Watch

Monitor Q1 2026 earnings in April for evidence that the 9.1% revenue growth rate holds or accelerates. Track OMNYPULSE and VARIPULSE adoption metrics once they move beyond trial data into commercial deployment, as real-world uptake will determine whether the atrial fibrillation franchise becomes a meaningful revenue driver. Watch for any regulatory setbacks or competitive moves in the prostate cancer space that could undermine ERLEADA’s market position. If JNJ breaks above $240 decisively on volume, the next resistance sits near $265 where analyst targets cluster; a failure to hold $235 on any pullback would signal weakening momentum. Pay attention to debt management and capital allocation decisions in upcoming earnings calls, particularly around M&A activity or dividend sustainability if free cash flow disappoints. Finally, monitor macroeconomic data on healthcare spending and insurance coverage changes, as these directly affect demand for JNJ’s portfolio across oncology, immunology, and cardiovascular franchises.

Analyst Consensus

BUY

Based on 24 analyst opinions

Low Target

$155.00

Mean Target

$231.25

High Target

$265.00

Earnings and Financial Data

Sector

Healthcare

Industry

Drug Manufacturers – General

Employees

N/A

Earnings & Dividends

Next Earnings

Apr 14, 2026

EPS (Trailing)

$11.03

Dividend Yield

219.0%

Payout Ratio

46.6%

Frequently Asked Questions

Is JNJ a good stock to buy?

JNJ currently shows a strong analyst recommendation with a “BUY” rating and a target price of $231.25. With a P/E ratio of 21.68 and consistent growth in the healthcare sector, JNJ presents an attractive investment opportunity.

What is JNJ’s price target?

Analysts have set a target price of $231.25 for JNJ. This means there is potential for a price decline given the current trading price of $239.15.

Does JNJ pay a dividend?

Yes, Johnson & Johnson has a dividend yield of 219.0%. This makes it appealing for income-focused investors, given its history of steady dividend payments.

What is JNJ’s market cap?

JNJ has a market capitalization of approximately $576.18 billion. This positions it as one of the major players in the healthcare industry, indicating robust financial health.

What is JNJ’s recent stock performance?

The stock has traded within a 52-week range of $141.50 to $240.24. The current price of $239.15 places it near its peak, suggesting bullish sentiment among investors.

Related Stock Reports

Disclaimer: This report is for informational purposes only and does not constitute financial advice. The analysis and opinions expressed are those of AltStation.io and should not be relied upon as the sole basis for investment decisions. Always conduct your own research and consult with a qualified financial advisor before making investment decisions. Past performance does not guarantee future results. Updated February 07, 2026.